Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Rapid Communication
Pilot Study of Short-Term Effects of a Novel Long-Acting Oral Beraprost in Patients With Pulmonary Arterial Hypertension
Daisuke IkedaIchizo TsujinoShinji SakaueHiroshi OhiraNaofumi ItohMitsunori KamigakiShinji IshimaruTatsuya AtsumiMasaharu Nishimura
Author information
JOURNAL FREE ACCESS

2007 Volume 71 Issue 11 Pages 1829-1831

Details
Abstract

Background Oral prostacyclin analogs can improve the prognosis of patients with mild to moderate pulmonary arterial hypertension (PAH), but because they often provoke adverse effects, such as flushing and dizziness, administering the optimal dose can be difficult. Methods and Results In the present study, a novel long-acting oral beraprost (TRK-100STP: 0-360 μg/day for 12 weeks) was administered to 4 patients with mild to moderate PAH. The patients tolerated the drug well with mild adverse manifestations and negligible effects on the systemic circulation. In contrast, pulmonary vascular resistance decreased by 27±12% and the 6-min walk test distance increased by 11±11%. Conclusions TRK-100STP is a novel option in the medical management of patients with PAH. (Circ J 2007; 71: 1829 -1831)

Content from these authors
© 2007 THE JAPANESE CIRCULATION SOCIETY
Previous article Next article
feedback
Top